We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

The MarketWatch News Department was not involved in the creation of this content. -- Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® ...

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, announced a clinical trial collaboration with BioNTech to evaluate a novel immuno-oncology combination in ...